GenVec Announces Interim Survival Data In Pivotal Trial Of TNFerade? In Locally Advanced Pancreatic Cancer

GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade? (PACT) in patients with locally advanced pancreatic cancer. This interim analysis of overall survival, conducted after the 92nd death (one-third of total expected events), was designed to determine whether the study should continue and took place in the time frame originally estimated.

More: continued here

Filed under: Cancer on November 21st, 2008